High-dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer: a phase II study. EORTC Genito-Urinary Tract Cancer Co-operative Group. EORTC Early Clinical Trials Group

G Stoter; A Akdas; S D Fosså; S B Kaye; C J van Groeningen; J Renard; M van Glabbeke

doi:10.1093/oxfordjournals.annonc.a058266

High-dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer: a phase II study. EORTC Genito-Urinary Tract Cancer Co-operative Group. EORTC Early Clinical Trials Group

Ann Oncol. 1992 Jul;3(7):577-8. doi: 10.1093/oxfordjournals.annonc.a058266.

Authors

G Stoter¹, A Akdas, S D Fosså, S B Kaye, C J van Groeningen, J Renard, M van Glabbeke

Affiliation

¹ Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.

PMID: 1323325
DOI: 10.1093/oxfordjournals.annonc.a058266

Abstract

Eighteen patients with progressive disseminated, platinum-resistant germ cell tumors were treated with epirubicin 135 mg/m2, every 3 weeks. One patient had stable disease, 17 developed progression. Myelosuppression was dose-limiting. One patient died of neutropenic septicemia. High-dose epirubicin is not active against platinum-resistant germ cell cancer.

Publication types

Clinical Trial

MeSH terms

Adolescent
Adult
Drug Evaluation
Epirubicin / therapeutic use*
Humans
Middle Aged
Neoplasms, Germ Cell and Embryonal / drug therapy*

Substances

Epirubicin